Cargando…

Role of Type 1 Interferons therapy on Adverse Clinical Outcomes on COVID-19 in Hospitalized Multiple Sclerosis Patients

OBJECTIVE(S): Type 1 Interferons (IFNs) modulate the antiviral immune response and have been used for the treatment of coronaviruses. This study aimed to determine any possible effects and safety concerns of the two most promising exogenously administrable interferons (IFNβ1a and IFNβ1b) on the seve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maghbooli, Zhila, Sahraian, Mohammad Ali., Fattahi, Mohammad Reza, Varzandi, Tarlan, Hamtaeigashi, Sara, Mohammad-Nabi, Sara, Aghababaei, Yasaman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2023
Materias:	Msc2022-a-2090
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065165/ http://dx.doi.org/10.1016/j.msard.2022.104262

Ejemplares similares

Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection
por: Maghbooli, Zhila, et al.
Publicado: (2022)

Is Body Mass Index (BMI) Associated with Risk and Outcomes of COVID-19 in Iranian Multiple Sclerosis Patients?
por: Rezaeimanesh, Nasim, et al.
Publicado: (2023)

Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of COVID-19 in Multiple Sclerosis: A MENACTRIMS Registry Based Study
por: Zeineddine, Maya, et al.
Publicado: (2023)

Reduction in circulating vitamin D binding protein in patients with multiple sclerosis
por: Maghbooli, Zhila, et al.
Publicado: (2021)

Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-Cov-2 in Patients with Multiple Sclerosis on B-Cell Depleters
por: Conte, William L., et al.
Publicado: (2023)

Real-World Experience on the Use of COVID-19 Vaccination in Multiple Sclerosis Patients Treated with Cladribine Tablets Participating in the ADVEVA® Patient Support Program within the Gulf and Latin American Regions
por: Rodas, María Isabel Zuluaga, et al.
Publicado: (2023)

Use of Social Media Tools during COVID-19 Pandemic Among MS Fellowships and Patients
por: Mokhberdezfuli, Mahdieh, et al.
Publicado: (2023)

CNS Complications Following COVID-19 Vaccines: an Egyptian Case Series.
por: Salama, Sara, et al.
Publicado: (2023)

The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder
por: Maghbooli, Zhila, et al.
Publicado: (2021)

Community Eye Health MSc dissertations
Publicado: (2008)

Multiple sclerosis and human leukocyte antigen genotypes: Focus on the Middle East and North Africa region
por: Maghbooli, Zhila, et al.
Publicado: (2020)

Treatment With 25-Hydroxyvitamin D(3) (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
por: Maghbooli, Zhila, et al.
Publicado: (2021)

Bone mineral density and muscle mass in adults with developmental skeletal discrepancies
por: Sharifi, Reza, et al.
Publicado: (2022)

Adipocytokine Profile, Cytokine Levels and Foxp3 Expression in Multiple Sclerosis: a Possible Link to Susceptibility and Clinical Course of Disease
por: Emamgholipour, Solaleh, et al.
Publicado: (2013)

Correction: Adipocytokine Profile, Cytokine Levels and Foxp3 Expression in Multiple Sclerosis: a Possible Link to Susceptibility and Clinical Course of Disease
por: Emamgholipour, Solaleh, et al.
Publicado: (2013)

Correction: Adipocytokine Profile, Cytokine Levels and Foxp3 Expression in Multiple Sclerosis: a Possible Link to Susceptibility and Clinical Course of Disease
por: Emamgholipour, Solaleh, et al.
Publicado: (2014)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
por: Malekzadeh, Masoud Mohammad, et al.
Publicado: (2020)

Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports
por: Rastkar, Mohsen, et al.
Publicado: (2023)

Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis
por: Baghizadeh, Somayyeh, et al.
Publicado: (2016)

Disease‐modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta‐analysis
por: Valizadeh, Amir, et al.
Publicado: (2022)

SCCmec Genotypes of Methicillin-Resistant Staphylococcus aureus in Nasal Carriage of Multiple Sclerosis Patients in Iran
por: JAMSHIDI, Yasaman, et al.
Publicado: (2019)

Correlation between the clinical disability and T1 hypointense lesions’ volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta‐analysis
por: Valizadeh, Amir, et al.
Publicado: (2021)

Assessment of COVID-19 vaccine attitude in people with multiple sclerosis, its correlation with demographic factors, and fear of coronavirus: A cross-sectional survey
por: Fattahi, Mohammad Reza, et al.
Publicado: (2022)

Translation and validation of the Persian version of Godin Leisure-Time Exercise Questionnaire in patients with multiple sclerosis
por: Fattahi, Mohammad-Reza, et al.
Publicado: (2021)

TURNING THE OXYGEN DIAL AS A THERAPY: HYPOXIA TREATMENT FOR MITOCHONDRIAL DYSFUNCTION
por: Jain, Isha
Publicado: (2019)

MITOCHONDRIA AS REVERSIBLE REGULATORS OF AGING ASSOCIATED SKIN WRINKLES AND HAIR LOSS IN MICE
por: Singh, Keshav K
Publicado: (2019)

DOES AUGMENTATION OF MITOCHONDRIAL THIOREDOXIN REDUCTASE 2 IMPROVE METABOLIC FITNESS?
por: Chocron, Sandra, et al.
Publicado: (2019)

IS AGING AN ACQUIRED MITOCHONDRIAL DISEASE?
por: Bitto, Alessandro
Publicado: (2019)

AGING AND MITOCHONDRIAL DISEASE: SHARED MECHANISMS AND THERAPIES?
por: Bitto, Alessandro, et al.
Publicado: (2019)

Prevalence of Multiple Sclerosis (MS) in Zanjan Province of Iran
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2020)

Pension Fund - Annual Information Meeting
por: Malmberg, Ossi, et al.
Publicado: (2022)

Wat staat ons te wachtenin 2022?
por: Berends, Nienke, et al.
Publicado: (2022)

The Factors Associated With Olfactory Dysfunction in Patients with Multiple Sclerosis
por: Almasi, Mostafa, et al.
Publicado: (2021)

Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
por: Molazadeh, Negar, et al.
Publicado: (2023)

Blood Concentrations of Cadmium and Lead in Multiple Sclerosis Patients from Iran
por: Aliomrani, Mehdi, et al.
Publicado: (2016)

Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV
por: Ali Sahraian, Mohammad, et al.
Publicado: (2021)

Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection
por: Maghbooli, Zhila, et al.
Publicado: (2020)

Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis
por: Fattahi, Mahtab, et al.
Publicado: (2020)

The prevalence of multiple sclerosis in Tehran, Iran, in 2020
por: Eskandarieh, Sharareh, et al.
Publicado: (2023)

Association Study of Estrogen Receptor Alpha Gene Polymorphisms with Spontaneous Abortion: Is This a Possible Reason for Unexplained Spontaneous Abortion?
por: Anousha, Negin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e5kdekq5qkumos3n31ssq33bjj